Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes

Ioannides-Demos, L.L.; Ibrahim, J.E.; McNeil, J.J.; Ioannides-Demos, Lisa L; Ibrahim, Joseph E; McNeil, John J
July 2002
PharmacoEconomics;2002, Vol. 20 Issue 9, p577
Academic Journal
journal article
Pharmaceutical expenditure is rising more rapidly than the general inflation rate in most advanced countries. One strategy that has been introduced to control pharmaceutical costs is reference-based pricing (RBP). Its potential is restricted to those specific segments of the drug market where several drugs (and/or their generic forms) exist without substantial evidence that any particular agent is superior. Three broad approaches have been adopted. These involve the aggregation of drugs into generic groups, related drug groups (e.g. ACE inhibitors) or drugs grouped by therapeutic indication (e.g. antihypertensives). For each drug group, a single reimbursement level or reference price is set. Drugs above the reference price require part or total payment by the patient. The experience with RBP ranges from over 10 years in Germany (involving all levels of RBP) to the more recent implementation of RBP for related drug groups in Australia. This review summarises the current state of knowledge on RBP from the published experiences in the countries where RBP has been adopted. The published systematic reviews of RBP from the countries that have implemented it suggest that RBP has been successful at temporarily capping drug prices for the RBP drug groups and achieving short term cost savings. However, other factors influencing total pharmaceutical expenditure have often occurred simultaneously and make it difficult to isolate specific effects of RBP. Further investigation is required before any valid conclusions can be drawn about the net effect of RBP on healthcare costs. RBP has withstood the initial legal challenges of pharmaceutical companies and the criticisms of some clinicians. Where the reference price is based on the lowest priced drug(s) in the group, RBP appears to be one of the few strategies likely to be effective at encouraging doctors to use the least expensive agents as first-line therapy and utilise more expensive agents in those who experience side effects or poor efficacy.


Related Articles

  • Perspectives On The Pharmaceutical Industry. Reinhardt, Uwe E. // Health Affairs;2001 A Primer, p128 

    Characterizes the pharmaceutical industry in the United States. Cost structure of the industry; Effect of drug spending on the economy; Drug spending as a percentage of gross domestic product; Pharmaceutical profits as a source of cost containment; Cost sharing by patients; Price discrimination.

  • Do we pay too much for prescriptions?  // Consumer Reports;Oct93, Vol. 58 Issue 10, p668 

    Examines reasons why prescription drugs are priced highly. Pharmaceutical industry as first targets of health-care reform; Price raising during the 1980s; Profits earned by drug companies; Profits as necessary to attract capital for research and development; Price decisions as within the...

  • Gov't to delay drug price rises. Csonka, Agnes // Budapest Business Journal;06/10/2002, Vol. 10 Issue 27, p4 

    Reports on the Hungarian government's plan of delaying a proposed price increase in prescription drugs receiving state subsidies by six months. Price increase for National Health Fund Administration-subsidized medications by an average of 5 percent; Plans to hike the prices of over-the-counter...

  • Prescription market booms with volume growth accelerating. Roller, Kim // Drug Store News;5/22/2000, Vol. 22 Issue 7, p51 

    Focuses on the retail drug prescription market in 1999 in the United States. Market share of chain drug stores; Increase in mail-order sales; Continued increase in prescription volume; Price increase for branded pharmaceuticals.

  • Industry unwilling to give an inch to gain a mile. Tosh, Mark // Drug Store News;8/12/2002, Vol. 24 Issue 10, p14 

    Comments on the unwillingness of the U.S. pharmaceutical industry to compromise in order to support the legislation that would provide prescription drug benefit under Medicare. Concerns of drug makers on price controls; Outlook of community pharmacy chains on the mail ordering of drugs.

  • Drug firms shuffle Rx discount cards. Ukens, Carol // Drug Topics;5/6/2002, Vol. 146 Issue 9, p26 

    Reports on the Together Rx prescription drug discount card offered by pharmaceutical companies in the U.S. Pharmaceutical companies that offer the discount card; Information on the amount of discount offered by the card; Difference of the Together Rx card from other prescription drug discount...

  • MAINE'S PRESCRIPTION DRUG PLAN: A LOOK INTO THE CONTROVERSY. Phelps, Whitney Magee // Albany Law Review;2001, Vol. 65 Issue 1, p243 

    Explores Maine's attempt to provide its citizens with affordable medications and prescription drugs. Reason prescription drugs are costly to the elderly in the U.S.; Controversy surrounding Maine's solution; Details of the constitutionality of Maine's healthcare program.

  • Restrictive formularies may increase costs. Schachner, Michael // Business Insurance;3/25/96, Vol. 30 Issue 13, p3 

    Looks at the findings of a study pertaining to prescription drug formularies, report by the National Pharmaceutical Council. Details of the study Managed Care Outcomes Project; Basis of the study; Conclusion of Susan Horn, Institute for Clinical Outcomes Research.

  • THE NEXT BOGEYMAN? Gay, Verne // Brandweek;09/18/2000, Vol. 41 Issue 36, pE12 

    Focuses on the efforts of Citizens for Better Medicare (CBM) to campaign against government attempts to control prescription drug prices in the United States (U.S.). How CBM is funded by the pharmaceutical industry; Cost of the advertising and lobbying efforts of CBM in 1999; Criticisms of U.S....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics